Skip to main content
Figure 1 | Trials

Figure 1

From: A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial

Figure 1

Time schedule of enrolment, interventions, and assessments for participants. Routine tests (APTT, platelets, D-dimer, AT, leukocytes, CRP, PCT, hematocrit), anti-Xa, and urine and plasma NGAL and Cr are measured at baseline. Following randomization, the patient will receive sc enoxaparin according to group allocation. Bedside clinical assessment for VTE and bleeding using validated scoring systems (Well's scores, HEME tool) will be conducted, and samples for hematocrit and platelet count will be taken daily. Bilateral lower extremity CUS will be conducted on the 1st, 3rd and 7th day of inclusion. Once weekly CUS (more frequent if DVT is suspected), as well as samples for peak anti-Xa (measured at 4 hours after enoxaparin dose) and trough anti-Xa (measured at 20 hours after enoxaparin dose) will be taken. Spiral pulmonary CT angiography and echocardiography will be performed on clinical suspicion of PE. During CRRT-free intervals with CrCl <30 ml/min/1.73 m2, group allocation will be discontinued and participants will receive 40 mg enoxaparin QD until the CrCl is >30 ml/min/1.73 m2 when enoxaparin dose according to group allocation will be resumed. Samples of urine and plasma will be taken for NGAL and Cr during CRRT-free intervals. APTT, Activated partial thromboplastin time; anti-Xa, Antifactor Xa; AT, Antithrombin; CRP, C-reactive protein; PCT, Procalcitonin; NGAL, Neutrophil gelatinase-associated lipocalin; Cr, Creatinine; sc, subcutaneous; VTE, Venous thromboembolism; CUS, Compression ultrasound; DVT, Deep venous thrombosis; CT, Computed tomography; PE, Pulmonary emboli; CRRT, Continuous renal replacement therapy; CrCl, Creatinine Clearance; QD, Once daily; HIT, Heparin-induced thrombocytopenia; ICU, Intensive care unit.

Back to article page